Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

Mostrar otras versiones (1)

<h4>Background</h4>The phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its high cost, this study ai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qiao Liu, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, Xiaohui Zeng
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c132ce149e7d47f49d7a7e8fbb5d050f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares